Insider Selling: Prometheus Biosciences, Inc. (NASDAQ:RXDX) CEO Sells $2,974,750.00 in Stock
Insider Selling: Prometheus Biosciences, Inc. (NASDAQ:RXDX) CEO Sells $2,974,750.00 in Stock
Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) CEO Mark C. Mckenna sold 25,000 shares of the stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $118.99, for a total value of $2,974,750.00. Following the transaction, the chief executive officer now directly owns 55,144 shares in the company, valued at approximately $6,561,584.56. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
普羅米修斯生物科學公司(納斯達克代碼:RXDX-GET Rating)首席執行官馬克·C·麥肯納在1月17日(星期二)的交易中出售了25,000股普羅米修斯股票。這些股票的平均價格為118.99美元,總價值為2974,750.00美元。交易完成後,首席執行官現在直接擁有公司55,144股,價值約6,561,584.56美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過此超鏈接.
Prometheus Biosciences Price Performance
普羅米修斯生物科學公司性價比
Shares of RXDX stock opened at $115.00 on Friday. The stock has a 50 day moving average of $87.83 and a two-hundred day moving average of $61.97. The company has a current ratio of 11.19, a quick ratio of 11.19 and a debt-to-equity ratio of 0.11. Prometheus Biosciences, Inc. has a 12 month low of $21.50 and a 12 month high of $122.75. The company has a market capitalization of $4.82 billion, a P/E ratio of -34.33 and a beta of -0.48.
上週五,RXDX的股票開盤報115.00美元。該股的50日移動均線切入位為87.83美元,200日移動均線切入位為61.97美元。該公司的流動比率為11.19,速動比率為11.19,債務權益比率為0.11。普羅米修斯生物科學公司的12個月低點為21.5美元,12個月高位為122.75美元。該公司市值為48.2億美元,市盈率為-34.33,貝塔係數為-0.48。
Prometheus Biosciences (NASDAQ:RXDX – Get Rating) last announced its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.01). Prometheus Biosciences had a negative return on equity of 61.37% and a negative net margin of 1,847.71%. The firm had revenue of $0.97 million during the quarter, compared to the consensus estimate of $0.77 million. As a group, equities analysts expect that Prometheus Biosciences, Inc. will post -3.43 EPS for the current year.
普羅米修斯生物科學公司(納斯達克代碼:RXDX-GET評級)上一次公佈季度收益數據是在11月9日星期三。這家生物製藥公司公佈了該季度每股收益(0.90美元),低於分析師普遍預期的(0.89美元)和(0.01美元)。普羅米修斯生物科學公司的淨資產回報率為負61.37%,淨利潤率為負1847.71%。該公司本季度營收為97萬美元,而市場普遍預期為77萬美元。作為一個整體,股票分析師預計普羅米修斯生物科學公司本年度每股收益將為3.43歐元。
Hedge Funds Weigh In On Prometheus Biosciences
對衝基金參與普羅米修斯生物科學公司
Analyst Upgrades and Downgrades
分析師升級和下調評級
A number of research analysts have recently commented on the company. Royal Bank of Canada increased their price objective on Prometheus Biosciences from $66.00 to $111.00 in a report on Wednesday, December 7th. Wells Fargo & Company increased their target price on Prometheus Biosciences from $71.00 to $164.00 in a research note on Thursday, December 8th. BTIG Research increased their target price on Prometheus Biosciences from $74.00 to $181.00 and gave the company a "buy" rating in a research note on Thursday, December 8th. Oppenheimer increased their target price on Prometheus Biosciences from $61.00 to $125.00 and gave the company an "outperform" rating in a research note on Thursday, December 8th. Finally, Stifel Nicolaus increased their target price on Prometheus Biosciences from $50.00 to $55.00 and gave the company a "buy" rating in a research note on Tuesday, November 1st. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Prometheus Biosciences currently has a consensus rating of "Buy" and an average price target of $107.80.
一些研究分析師最近對該公司發表了評論。加拿大皇家銀行在12月7日星期三的一份報告中將他們對普羅米修斯生物科學公司的目標價從66美元上調至111.00美元。富國銀行8日週四在一份研究報告中將普羅米修斯生物科學公司的目標價從71美元上調至164.00美元。BTIG Research在12月8日週四的一份研究報告中將其對普羅米修斯生物科學公司的目標價從74美元上調至181.00美元,並給予該公司“買入”評級。奧本海默在12月8日週四的一份研究報告中將他們對普羅米修斯生物科學公司的目標價從61美元上調至125.00美元,並給出了該公司“跑贏大盤”的評級。最後,Stifel Nicolaus在11月1日星期二的一份研究報告中將其對普羅米修斯生物科學公司的目標價從50.00美元上調至55.00美元,並給出了該公司“買入”的評級。根據MarketBeat的數據,9名研究分析師對該股的評級為買入,普羅米修斯生物科學公司目前的共識評級為“買入”,平均目標價為107.80美元。
Prometheus Biosciences Company Profile
普羅米修斯生物科學公司簡介
(Get Rating)
(獲取評級)
Prometheus Biosciences, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease.
普羅米修斯生物科學公司是一家生物製藥公司,致力於治療炎症性腸病(IBD)的新型療法和伴隨診斷產品的發現、開發和商業化。它的主要產品包括PRA023,一種人源化的IgG1單抗(MAb),正處於IIa期臨牀試驗,用於治療潰瘍性結腸炎和克羅恩病,以及系統性硬化症相關的間質性肺疾病。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Prometheus Biosciences (RXDX)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- 免費獲取StockNews.com關於普羅米修斯生物科學的研究報告(RXDX)
- 市場回顧周-1/16-1/20
- Old Dominion是否表明Trucking正在踩剎車?
- 諾德斯特龍對零售業降價的擔憂
- 埃克森美孚股票:在Buy Point附近
- 高股息率的必和必拓認為中國推動了23年的增長
Receive News & Ratings for Prometheus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prometheus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《普羅米修斯生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對普羅米修斯生物科學公司和相關公司的最新新聞和分析師評級的每日簡要摘要。